{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=15",
    "query": {
      "intervention": "Protein Control",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 3497,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T04:35:32.763Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03626376",
      "title": "Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex Virus Keratitis"
      ],
      "interventions": [
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily",
          "type": "DRUG"
        },
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-10",
      "completion_date": "2022-03-02",
      "has_results": false,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626376"
    },
    {
      "nct_id": "NCT00513474",
      "title": "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporin-A",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "rasburicase",
          "type": "DRUG"
        },
        {
          "name": "sirolimus",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2008-01",
      "completion_date": "2013-02-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-25",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00513474"
    },
    {
      "nct_id": "NCT05383508",
      "title": "Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nicotine Vaping",
        "Nicotine",
        "Vaping"
      ],
      "interventions": [
        {
          "name": "CA35",
          "type": "OTHER"
        },
        {
          "name": "CM35",
          "type": "OTHER"
        },
        {
          "name": "Cig",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Philip Morris Products S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "24 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-04-28",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05383508"
    },
    {
      "nct_id": "NCT00829140",
      "title": "To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lorcaserin 10mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 56,
      "start_date": "2008-11",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829140"
    },
    {
      "nct_id": "NCT05482334",
      "title": "Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "Sargramostim for Injection",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-10-23",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482334"
    },
    {
      "nct_id": "NCT07478016",
      "title": "EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Ductal Carcinoma In Situ"
      ],
      "interventions": [
        {
          "name": "Survey Assessments",
          "type": "OTHER"
        },
        {
          "name": "Diet Recall",
          "type": "OTHER"
        },
        {
          "name": "Blood Biomarker Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2022-12-21",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07478016"
    },
    {
      "nct_id": "NCT02266433",
      "title": "Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DeQuervains Tenosynovitis",
        "Lateral Epicondylitis",
        "Tennis Elbow",
        "Trigger Finger",
        "Tenosynovitis",
        "Inflammatory Disease"
      ],
      "interventions": [
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2012-08",
      "completion_date": "2018-07-01",
      "has_results": true,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266433"
    },
    {
      "nct_id": "NCT00624338",
      "title": "Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Atacicept 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Atacicept 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 461,
      "start_date": "2008-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624338"
    },
    {
      "nct_id": "NCT05031806",
      "title": "Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "iNexin™ (0.08% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "iNexin™ (0.4% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "iNexin™ (2.0% aCT1)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (eye drop formulation without aCT1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xequel Bio, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-28",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031806"
    },
    {
      "nct_id": "NCT05460871",
      "title": "Pregabalin for Central Sensitization in TKA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteo Arthritis Knee",
        "Central Nervous System Sensitization"
      ],
      "interventions": [
        {
          "name": "Pregabalin 75mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-02-21",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-10-24T04:35:32.763Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05460871"
    }
  ]
}